Home›Cardiology› Adding antiplatelet therapy to anticoagulation does not cut stroke risk but raises major bleeding
Adding antiplatelet therapy to anticoagulation does not cut stroke risk but raises major bleedingCombined Anticoagulant and Antiplatelet Therapy Increases Bleeding Risk
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyPublished August 26, 2026Study authors: Oliveira de Amorim Samuel, da Silva Ferreira Matheus, Soares Cid, Pereira Felipe Henrique Lima, Silv…PubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider OAC monotherapy as standard; avoid adding antiplatelet therapy due to increased bleeding without stroke reduction.
This is a meta-analysis of randomized and observational studies evaluating combined oral anticoagulation (OAC) plus antiplatelet therapy (APT) versus OAC monotherapy in patients with recent ischemic stroke, nonvalvular atrial fibrillation (NVAF), and large artery atherosclerosis (LAA). The analysis included 14,884 patients. The primary outcome was recurrent ischemic stroke; secondary outcomes were all-cause mortality and major bleeding.
For recurrent ischemic stroke, combined therapy showed no significant reduction compared with OAC monotherapy (RR 0.98, 95% CI 0.92-1.04; p = 0.55). All-cause mortality was not statistically significantly different (RR 1.11, 95% CI 0.98-1.26; p = 0.09), though the point estimate suggested a possible increase. Major bleeding was significantly increased with combined therapy (RR 1.49, 95% CI 1.04-2.15; p = 0.03).
The authors did not report limitations, funding, or conflicts of interest. Follow-up duration was not reported. The analysis is based on a meta-analysis of randomized and observational studies, so causality should be interpreted cautiously.
In practice, these findings support that OAC monotherapy should remain the standard of care for this patient population, and combined therapy should be avoided in routine practice. The increased bleeding risk without a corresponding reduction in stroke reinforces the importance of adhering to guideline-recommended anticoagulation alone.
How this fits prior evidence
This meta-analysis extends prior coverage on anticoagulation in atrial fibrillation by specifically addressing the role of adding antiplatelet therapy in patients with concurrent large artery atherosclerosis. While prior coverage noted that DOACs are associated with lower risks of stroke and hemorrhage in AF, this analysis shows that adding antiplatelet therapy to OAC does not further reduce recurrent ischemic stroke (RR 0.98) and increases major bleeding (RR 1.49). It contrasts with the notion that combination therapy might be beneficial in high-risk subgroups, and it reinforces the safety of OAC monotherapy, consistent with prior guidance on avoiding unnecessary combination therapy.
Researchers looked at data from over 14,000 patients who had recent strokes and specific heart conditions. They compared using one type of blood thinner against using two types together: an oral anticoagulant and antiplatelet therapy. The goal was to see if the combined treatment provided better protection against another stroke.
The results showed that adding a second medication did not significantly reduce the risk of having another ischemic stroke. However, patients who received both medications experienced a statistically significant increase in major bleeding events. This suggests that the extra medication may cause more harm than good for these specific conditions.
Because the combined therapy does not lower stroke rates but does increase bleeding, medical experts suggest that using just one blood thinner remains the standard of care. Patients with these conditions should talk to their doctors about the safest way to manage their medications.
What this means for you:
Combining two types of blood thinners may increase bleeding risk without reducing stroke rates in certain patients.
Common questions
Does taking two types of blood thinners prevent more strokes?
The study found no significant reduction in recurrent ischemic stroke when using combined therapy compared to just one type of blood thinner. The results showed a risk ratio of 0.98, which means the combination did not provide extra protection against another stroke for patients with these conditions.
Are there risks to combining anticoagulants and antiplatelet therapy?
Yes, the study found a statistically significant increase in major bleeding for those on combined therapy. The risk of major bleeding was higher by a factor of 1.49 compared to patients taking only one type of blood thinner.
What is the recommended treatment for these conditions?
Because the combination of medications increases bleeding without reducing stroke rates, oral anticoagulation monotherapy is currently considered the standard of care. Patients should consult their doctors to determine the safest treatment plan for their specific needs.
BACKGROUND: Treating ischemic stroke patients who have both nonvalvular atrial fibrillation (NVAF) and large artery atherosclerosis (LAA) presents a clinical challenge. It remains unclear whether adding antiplatelet therapy (APT) to oral anticoagulation (OAC) reduces stroke risk or only increases the danger of hemorrhage.
METHODS: We conducted a systematic review and meta-analysis of randomized and observational studies to compare OAC monotherapy against combined therapy (OAC + APT) in patients with recent ischemic stroke, NVAF, and LAA. PubMed, Embase, Scopus, Cochrane Library, and Web of Science were searched from inception to December 2025. We applied random-effects models to estimate Risk Ratios (RR).
RESULTS: Seven studies comprising 14,884 patients were included. Combined therapy was not associated with a significant reduction in recurrent ischemic stroke (RR 0.98; 95% CI: 0.92-1.04; p = 0.55) or all-cause mortality (RR 1.11; 95% CI: 0.98-1.26; p = 0.09) compared to OAC monotherapy. Conversely, the combined strategy was associated with a statistically significant increase in the risk of major bleeding (RR 1.49; 95% CI: 1.04-2.15; p = 0.03).
CONCLUSION: Our findings indicate that adding antiplatelets to anticoagulation in patients with stroke, AF, and LAA confers no real clinical benefit but significantly exacerbates hemorrhagic morbidity. Consequently, OAC monotherapy should remain the standard of care, while combined therapy should be avoided in routine practice.
